GRB2 and lymphoma: As mentioned in the introduction, BCR-ABL with a mutation at the tyrosine-177 residue – a high affinity-binding site for the Grb2 SH2 domain [13,14] – induced a T cell leukemia and lymphoma after a prolonged latent period [15-17].